FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897055654> ?p ?o ?g. }

• W2897055654 endingPage "61" @default.
• W2897055654 startingPage "55" @default.
• W2897055654 abstract "The pharmacokinetics, especially the volume of distribution (Vd), of ß-lactam antibiotics can be altered in critically ill patients. This can lead to decreased serum concentrations and a reduction in clinical cures. Ceftazidime/avibactam (CZA) is a new antimicrobial agent utilized in critically ill patients although its pharmacokinetics has not been well defined in these patients.In this study, the serum concentrations of CZA from adult patients treated in an intensive care unit (ICU) with standard dosing regimens were measured and both pharmacokinetic and pharmacodynamic parameters were computed. The pharmacodynamic analyses included Monte Carlo simulations to determine the probability of target attainment (PTA: free ceftazidime concentrations exceed the minimum inhibitory concentration [MIC] for 50% of the dosing interval; free avibactam concentrations exceed 1 mg/L over the dosing interval) and serum time-kill curves against multi-drug-resistant Enterobacteriaceae susceptible to CZA. Serum concentrations were measured in 10 critically ill patients at two, four, six, and eight hours after multiple doses (infused over two hours) of CZA.A significant linear relation between creatinine clearance and total body clearance was identified for both ceftazidime (R = 0.91) and avibactam (R = 0.88). The mean clearance, volume of distribution, and half-life for ceftazidime were 6.1 ± 3.8 L/h, 35 ± 10.5 L, and 4.8 ± 2.15 h, respectively. For avibactam, these values were 11.1 ± 6.8 L/h, 50.8 ± 14.3 L, and 4.1 ± 2.1 h, respectively. Ceftazidime/avibactam achieved optimal PTA for bacteria with MICs of 16 mg/L or less. Furthermore, time-kill experiments revealed that serum concentrations of CZA, at each collection time, exhibited bactericidal (≥ 3 log10 CFU/mL reduction) activity against each of the study isolates.In conclusion, our study results suggest that the current dosing regimens of CZA can provide effective antimicrobial activity in ICU patients against CZA-susceptible (MIC ≤8 mg/L) isolates." @default.
• W2897055654 created "2018-10-26" @default.
• W2897055654 creator A5007386966 @default.
• W2897055654 creator A5019617495 @default.
• W2897055654 creator A5025500071 @default.
• W2897055654 creator A5040179120 @default.
• W2897055654 creator A5055862200 @default.
• W2897055654 creator A5075604195 @default.
• W2897055654 creator A5088382872 @default.
• W2897055654 creator A5090657231 @default.
• W2897055654 creator A5090740872 @default.
• W2897055654 date "2019-01-01" @default.
• W2897055654 modified "2023-09-27" @default.
• W2897055654 title "Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients" @default.
• W2897055654 cites W1789737085 @default.
• W2897055654 cites W1963802535 @default.
• W2897055654 cites W1977116686 @default.
• W2897055654 cites W1987570760 @default.
• W2897055654 cites W1996635339 @default.
• W2897055654 cites W2066745723 @default.
• W2897055654 cites W2069923587 @default.
• W2897055654 cites W2090598659 @default.
• W2897055654 cites W2101004558 @default.
• W2897055654 cites W2101416655 @default.
• W2897055654 cites W2128645382 @default.
• W2897055654 cites W2129122463 @default.
• W2897055654 cites W2136028041 @default.
• W2897055654 cites W2141173497 @default.
• W2897055654 cites W2145226012 @default.
• W2897055654 cites W2153171442 @default.
• W2897055654 cites W2154838792 @default.
• W2897055654 cites W2175383952 @default.
• W2897055654 cites W2205651284 @default.
• W2897055654 cites W2262202809 @default.
• W2897055654 cites W2339454548 @default.
• W2897055654 cites W2740182805 @default.
• W2897055654 cites W2742813652 @default.
• W2897055654 cites W2745939174 @default.
• W2897055654 cites W2773548512 @default.
• W2897055654 cites W2777458439 @default.
• W2897055654 cites W2796052358 @default.
• W2897055654 doi "https://doi.org/10.1089/sur.2018.141" @default.
• W2897055654 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30351195" @default.
• W2897055654 hasPublicationYear "2019" @default.
• W2897055654 type Work @default.
• W2897055654 sameAs 2897055654 @default.
• W2897055654 citedByCount "35" @default.
• W2897055654 countsByYear W28970556542019 @default.
• W2897055654 countsByYear W28970556542020 @default.
• W2897055654 countsByYear W28970556542021 @default.
• W2897055654 countsByYear W28970556542022 @default.
• W2897055654 countsByYear W28970556542023 @default.
• W2897055654 crossrefType "journal-article" @default.
• W2897055654 hasAuthorship W2897055654A5007386966 @default.
• W2897055654 hasAuthorship W2897055654A5019617495 @default.
• W2897055654 hasAuthorship W2897055654A5025500071 @default.
• W2897055654 hasAuthorship W2897055654A5040179120 @default.
• W2897055654 hasAuthorship W2897055654A5055862200 @default.
• W2897055654 hasAuthorship W2897055654A5075604195 @default.
• W2897055654 hasAuthorship W2897055654A5088382872 @default.
• W2897055654 hasAuthorship W2897055654A5090657231 @default.
• W2897055654 hasAuthorship W2897055654A5090740872 @default.
• W2897055654 hasConcept C111113717 @default.
• W2897055654 hasConcept C112705442 @default.
• W2897055654 hasConcept C139254425 @default.
• W2897055654 hasConcept C2775933652 @default.
• W2897055654 hasConcept C2776968632 @default.
• W2897055654 hasConcept C2777288759 @default.
• W2897055654 hasConcept C2777406300 @default.
• W2897055654 hasConcept C2777637488 @default.
• W2897055654 hasConcept C501593827 @default.
• W2897055654 hasConcept C523546767 @default.
• W2897055654 hasConcept C54355233 @default.
• W2897055654 hasConcept C71924100 @default.
• W2897055654 hasConcept C86803240 @default.
• W2897055654 hasConcept C89423630 @default.
• W2897055654 hasConcept C98274493 @default.
• W2897055654 hasConceptScore W2897055654C111113717 @default.
• W2897055654 hasConceptScore W2897055654C112705442 @default.
• W2897055654 hasConceptScore W2897055654C139254425 @default.
• W2897055654 hasConceptScore W2897055654C2775933652 @default.
• W2897055654 hasConceptScore W2897055654C2776968632 @default.
• W2897055654 hasConceptScore W2897055654C2777288759 @default.
• W2897055654 hasConceptScore W2897055654C2777406300 @default.
• W2897055654 hasConceptScore W2897055654C2777637488 @default.
• W2897055654 hasConceptScore W2897055654C501593827 @default.
• W2897055654 hasConceptScore W2897055654C523546767 @default.
• W2897055654 hasConceptScore W2897055654C54355233 @default.
• W2897055654 hasConceptScore W2897055654C71924100 @default.
• W2897055654 hasConceptScore W2897055654C86803240 @default.
• W2897055654 hasConceptScore W2897055654C89423630 @default.
• W2897055654 hasConceptScore W2897055654C98274493 @default.
• W2897055654 hasIssue "1" @default.
• W2897055654 hasLocation W28970556541 @default.
• W2897055654 hasLocation W28970556542 @default.
• W2897055654 hasOpenAccess W2897055654 @default.
• W2897055654 hasPrimaryLocation W28970556541 @default.
• W2897055654 hasRelatedWork W2132908812 @default.

• next